Bibliography
- Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115:118-22
- Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? Curr Opin Allergy Clin Immunol 2009;9:477-81
- Cox L. Allergic conjunctivitis. Allergy Clin Immunol Int J World Allergy Organ 2007;19:4-8
- Berdy GJ, Berdy SS. Ocular allergic disorders: disease entities and differential diagnoses. Curr Allergy Asthma Rep 2009;9(4):297-303
- Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11(5):471-6
- Alexander M, Berger W, Buchholz P, et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 2005;3:67
- Bielory L. Ocular allergy. Mt Sinai J Med 2011;78(5):740-58
- Sy H, Bielory L. Atopic keratoconjunctivitis. Allergy Asthma Proc 2013;34(1):33-41
- De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol 2013;97(1):9-14
- Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):83-103
- Bielory BP, O’Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol 2012;90(5):399-407
- Huang JF, Thurmond RL. The new biology of histamine receptors. Curr Allergy Asthma Rep 2008;8:21-7
- Chigbu D. The management of allergic eye disease in primary care. Cont Lens Anterior Eye 2009;32(6):260-72
- Baiula M, Bedini A, Carbonari G, et al. Therapeutic targeting of eosinophil adhesion and accumulation in allergic conjunctivitis. Front Pharmacol 2012;3:203
- Leonardi A. Allergy and allergic mediators in tears. Exp Eye Res 2013;117:106-17
- Ebihara N, Funaki T, Takai S, et al. Tear chymase in vernal keratoconjunctivitis. Curr Eye Res 2004;28:417-20
- Wakamatsu TH, Tanaka M, Satake Y, et al. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis. Mol Vis 2011;17:932-8
- Anonymous Drugs for allergic disorders. Treat Guide Med Lett 2010;9:9-18
- Qasem AR, Bucolo C, Baiula M, et al. Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol 2008;76:751-62
- Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-28
- Abelson MB, Kaplan AP. A randomized, double-blind, placebo controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model. Clin Ther 2002;24:445-56
- Secchi A, Ciprandi G, Leonardi A, et al. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl 2000;230:42-7
- Williams PB, Crandall E, Sheppard JD. Azelastine hydrochloride, a dual acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis. Clin Ophthalmol 2010;4:993-1001
- Mishra GP, Tamboli V, Jwala J, et al. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 2011;5:26-36
- Kida T, Fujii A, Sakai O, et al. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res 2010;91(1):85-91
- Carr WW, Nayak AS, Ratner PH, et al. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. Allergy Asthma Proc 2013;34(3):247-54
- Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther 2011;5:77-84
- Mizutani N, Aoki Y, Nabe T, et al. Effect of TA-270, a novel quinolinone derivative, on antigen-induced nasal blockage in a guinea pig model of allergic rhinitis. Eur J Pharmacol 2009;602:138-42
- Mahvan TD, Buckley WA, Hornecker JR. Alcaftadine for the prevention of itching associated with allergic conjunctivitis. Ann Pharmacother 2012;46(7-8):1025-32
- Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci 2012;16(14):1999-2005
- Maiti R, Rahman J, Jaida J, et al. Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg 2010;136(8):796-800
- Mandhane SN, Shah JH, Bahekar PC, et al. Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H. Int Arch Allergy Immunol 2010;151(1):56-69
- Effect of different concentrations of 1334H on allergic conjunctivitis. 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01320553?term=1334h&rank=1
- Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541-53
- Canonica GW, Ciprandi G, Petzold U, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003;19:321-9
- Finn DF, Walsh JJ. Twenty-first century mast cell stabilizers. Br J Pharmacol 2013;170(1):23-37
- Kidd M, McKenzie SH, Steven I, et al. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol 2003;87(10):1206-11
- Horak F, Stübner P, Zieglmayer R, et al. Onset and duration of action of ketotifen 0.025% and emedastine 0.05% in seasonal allergic conjunctivitis: efficacy after repeated pollen challenges in the Vienna challenge chamber. Clin Drug Investig 2003;23(5):329-37
- Abelson MB, Ferzola NJ, McWhirter CL, et al. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr Allergy Immunol 2004;15(6):551-7
- Evaluation of the safety and efficacy of Ketotifen 4.0% patch as compared to placebo patch, Olopatadine 0.2% ophthalmic solution, and artificial tears in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis. 2009. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00836485?term=nct00836485&rank=1
- Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55(2):108-33
- Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003;81(4):378-82
- Bielory BP, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2010;10(5):469-77
- Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30(1):10-13
- Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009;25:365-72
- Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010;26:165-74
- Wan XC, Dimov V. Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis. Expert Opin Drug Metab Toxicol 2014;10(4):543-9
- Study evaluating the efficacy of administration of cyclosporine (low dose and high dose) and prednisolone acetate compared to its components and vehicle in patients with allergic conjunctivitis. 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01120132?term=nct01120132&rank=1
- Evaluation of efficacy of coadministration of FOV1101-00 and prednisolone acetate in patients with mild ongoing ocular allergic inflammation. 2009. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00833495?term=nct00833495&rank=1
- Valenta R, Campana R, Marth K, et al. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012;272(2):144-57
- Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy 2011;41:1235-46
- Lin SY, Erekosima N, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and/or asthma: comparative effectiveness review. Comparative Effectiveness Reviews, No. 111 Johns Hopkins University Evidence-based Practice Center Agency for Healthcare Research and Quality (US), Rockville, MD; 2013. Report No.: 13-EHC061-EF
- Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 2013;131(6):1155-67
- Study on pharmacodynamic parameter and tolerability with subcutaneous immunotherapy in grass pollen allergic patients. 2009. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00857779?term=nct00857779&rank=1
- Safety and tolerability of toleromune grass in grass allergic subjects with rhinoconjunctivitis. 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01166061?term=nct01166061&rank=1
- Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129(1):128-35
- Study of specific allergen immunotherapy in grass pollen allergic subjects with epicutanoeus allergen administration (ZU-SkinSIT-003). 2008. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00777374?term=nct00777374&rank=1
- Mauro M, Russello M, Incorvaia C, et al. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007;39(4):119-22
- Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59(1):45-53
- Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma – a placebo controlled study. Ann Allergy Asthma Immunol 1999;82(5):485-90
- Bernardis P, Agnoletto M, Puccinelli P, et al. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Investig Allergol Clin Immunol 1996;6(1):55-62
- Frati F, Incorvaia C, Passalacqua G. Efficacy of sublingual immunotherapy. JAMA 2013;310(6):643-4
- Bousquet J, van Cauwenberge P, Khaltaev N; ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):147-334
- Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118(2):434-40
- Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120(6):1338-45
- Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: cochrane systematic review and meta-analysis. Clin Exp Allergy 2011;41(9):1263-72
- Safety study of grass pollen-derived peptides to treat seasonal allergic rhinoconjunctivitis. 2009. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00833066?term=nct00833066&rank=1
- Safety of gpASIT+TM subcutaneously administered to hay fever patients with or without immunoregulating adjuvant. 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01506375?term=nct01506375&rank=1
- Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374(6522):546-9
- Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 2006;90(1):103-8
- Lambiase A, Micera A, Sacchetti M, et al. Toll-like receptors in ocular surface diseases: overview and new findings. Clin Sci (Lond) 2011;120(10):441-50
- Magone MT, Chan CC, Beck L, et al. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000;30:1841-50
- Klinman DM. Immunotherapeutic use of CpG oligodeoxynucleotides. Nat Rev 2004;4:249-58
- Dose finding study with CYT003-QbG10 in patients with house dust mite allergy. 2008. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00800332?term=cyt003-qbg10&rank=2
- Study to investigate an immunomodulatory therapy in adult patients with perennial allergic rhinoconjunctivitis. 2007. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00575003?term=cyt003-qbg10&rank=4
- A study to investigate an immunomodulatory therapy in adult patients with perennial allergic rhinoconjunctivitis. 2007. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00574223?term=cyt003-qbg10&rank=5
- Effect of an allergen vaccine in patients with allergic rhino-conjunctivitis and asthma due to house dust mite allergy. 2005. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00652223?term=cyt003-qbg10&rank=8
- Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39(4):562-70
- Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41(9):1305-12
- Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opin Pharmacother 2013;14(11):1449-65
- Mishra GP, Tamboli V, Jwala J, et al. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 2011;5(1):26-36
- Schäcke H, Schottelius A, Döcke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101(1):227-32
- Kato M, Hagiwara Y, Oda T, et al. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. J Ocul Pharmacol Ther 2011;27(4):353-60
- Shafiee A, Bucolo C, Budzynski E, et al. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 2011;52:1422-30
- Baiula M, Spartà A, Bedini A, et al. Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Mol Vis 2011;17:3208-23
- Baiula M, Bedini A, Baldi J, et al. Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy. Drug Des Devel Ther 2014;8:745-57
- Study to assess the safety and efficacy of BOL-303242-X ophthalmic suspension in dry eye syndrome. 2010. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01163643?term=nct01163643&rank=1
- Mapracorat ophthalmic formulation in subjects with allergic conjunctivitis. 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01289431?term=mapracorat&rank=6
- Mapracorat ophthalmic suspension, 3% for the treatment of ocular inflammation and pain following cataract surgery. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01591161?term=mapracorat&rank=3
- Leonardi A, Bremond-Gignac D, Bortolotti M, et al. Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. Br J Ophthalmol 2007;91(12):1662-6
- Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36(6):689-703
- Gane J, Buckley R. Leukotriene receptor antagonists in allergic eye disease: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2013;1(1):65-74
- Lambiase A, Bonini S, Rasi G, et al. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch Ophthalmol 2003;121(5):615-20
- Gronet K. Resolution, the grail for healthy ocular inflammation. Exp Eye Res 2010;91:478-85
- Alessandri AL, Sousa LP, Lucas CD, et al. Resolution of inflammation: mechanisms and opportunity for drug development. Pharmacol Ther 2013;139(2):189-212
- Dartt DA, Hodges RR, Li D, et al. Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol 2011;186(7):4455-66
- Li D, Hodges RR, Jiao J, et al. Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunol 2013;6(6):1119-30
- Lee CH. Resolvins as new fascinating drug candidates for inflammatory diseases. Arch Pharm Res 2012;35(1):3-7
- Evaluation of the onset and duration of action of RX-10045 in allergic conjunctivitis. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01639846?term=RX-10045&rank=2
- A study of RX-10045 in the treatment of dry eye disease. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01675570?term=RX-10045&rank=1
- Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia 2008;14(6):1261-8
- Watts P, Suresh P, Mezer E, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol 2002;133:451-5
- Heidemann DG, Williams GA, Hartzer M, et al. Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen. Cornea 2003;22:760-2
- Efficacy/safety of human plasminogen eye drop in ligneous conjunctivitis patients. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01554956?term=human+plasminogen&rank=1
- Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42(10):2283-92
- Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci USA 2013;110(10):3913-18
- A single center study for the treatment of moderate to severe allergic conjunctivitis (EBI-005-AC-1). 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02082899?term=ebi-005&rank=3
- Kelly M, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007;120(1):3-10
- Murphy CJ, Bentley E, Miller PE, et al. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. Invest Ophthalmol Vis Sci 2011;52(6):3174-80
- Sheppard JD, Torkildsen GL, Lonsdale JD, et al. OPUS-1 Study Group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology 2014;121(2):475-83
- Efficacy study to evaluate the effectiveness of 3 concentrations of SAR 1118 in allergic conjunctivitis. 2009. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00882687?term=lifitegrast&rank=5
- Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol 2008;153(Suppl 1):S191-9
- Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomized, placebo-controlled, double-blind trial. Allergy 2012;67(12):1572-9